| Literature DB >> 35540442 |
Gayatri Shankar Chilambi1,2, Iris H Gao2,3, Bo Kyeong Yoon4,5, Soohyun Park4,5, Lisa M Kawakami4, Vikashini Ravikumar2, Mary B Chan-Park6, Nam-Joon Cho4,5, Guillermo C Bazan6,7, Kimberly A Kline2,8, Scott A Rice2,8,9, Jamie Hinks2.
Abstract
The growing problem of antibiotic resistant bacteria, along with a dearth of new antibiotics, has redirected attention to the search for alternative antimicrobial agents. Conjugated oligoelectrolytes (COEs) are an emerging class of antimicrobial agents which insert into bacterial cell membranes and are inhibitory against a range of Gram-positive and Gram-negative bacteria. In this study, the extent of COE resistance that Enterococcus faecalis could achieve was studied. Enterococci are able to grow in hostile environments and develop resistance to membrane targeting antibiotics such as daptomycin in clinical settings. Herein we expand our knowledge of the antimicrobial mechanism of action of COEs by developing COE-resistant strains of E. faecalis OG1RF. Evolution studies yielded strains with a moderate 4-16 fold increase in antimicrobial resistance relative to the wild type. The resistant isolates accumulated agent-specific mutations associated with the liaFSR operon, which is a cell envelope-associated stress-response sensing and regulating system. The COE resistant isolates displayed significantly altered membrane fatty acid composition. Subsequent, exogenous supplementation with single fatty acids, which were chosen based on those dominating the fatty acid profiles of the mutants, increased resistance of the wild-type E. faecalis to COEs. In combination, genetic, fatty acid, and uptake studies support the hypothesis that COEs function through insertion into and disruption of membranes and that the mechanism by which this occurs is specific to the disrupting agent. These results were validated by a series of biophysical experiments showing the tendency of COEs to accumulate in and perturb adapted membrane extracts. Collectively, the data support that COEs are promising antimicrobial agents for targeting E. faecalis, and that there is a high barrier to the emergence of severely resistant strains constrained by biological limits of membrane remodeling that can occur in E. faecalis. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35540442 PMCID: PMC9078823 DOI: 10.1039/c7ra11823f
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1(a) Structures of COE1-3C and COE1-3Py (b) adaptation strategy for in vitro evolution – (i) Enterococcus faecalis OG1RF wild type, (ii) COE1-3C adapted strain and (iii) COE1-3Py adapted strain were used for the characterization studies indicated. Blue and green lines indicate evolution in COE1-3C and COE1-3Py. These strains were subjected to MIC tests, whole genome sequencing to identify mutations associated with the adaptations, fatty acid profile analysis and lastly, lipid extraction to study the biophysical interaction of COEs with lipid bilayers using quartz crystal microbalance-dissipation (QCM-D) and electrochemical impedance spectroscopy (EIS).
Minimum inhibitory concentrations of COE1-3C, COE1-3Py and daptomycin
| Strain | Description | Growth conditions | MIC | ||
|---|---|---|---|---|---|
| COE1-3C | COE1-3Py | Daptomycin | |||
|
| Wild type | BHI | 2 μM | 1 μM | 1.23 μM |
| EFC3C | COE1-3C resistant | BHI | 8 μM | 1 μM | 9.87 μM |
| EFC3Py | COE1-3Py resistant | BHI | 8 μM | 16 μM | 9.87 μM |
| DAP 21 | Daptomycin resistant | BHI | 2 μM | 1 μM | 78.96 μM |
| DAP 22 | Daptomycin resistant | BHI | 2 μM | 1 μM | 78.96 μM |
|
| Wild type | BHI + palmitic acid C16:0 (10 μg mL−1) | 2 μM | 1 μM | ND |
|
| Wild type | BHI + | 8 μM | 2 μM | ND |
|
| Wild type | BHI + | 8 μM | 4 μM | ND |
COE1-3C resistant strains with in frame deletion in liaF at position 179 and a substitution in the intergenic region between treB (PTS family trehalose porter, IIBC component) and gloA6 (lactoylglutathione lyase).
COE1-3Py resistant strains with a non-synonymous substitution at position 97 in the liaR gene.
DAP21 strains have mutations in cardiolipin synthase 1 (cls1; RF10364), a gene encoding a putative chaperone protein regulated by the liaFSR operon (RF11464) and hypothetical membrane protein (RF11507).[21]
DAP22 strains have mutations in gene encoding a putative chaperone protein regulated by the liaFSR operon (RF11464) and hypothetical membrane protein (RF11507) along with mutations in cardiolipin synthase 2 (cls2; RF11324) and a putative metal-dependent HD-domain-containing hydrolase (RF11901).[21] ND – not determined.
Single nucleotide polymorphisms in COE1-3C and COE1-3Py resistant strains EFC3C and EFC3Py
| Gene locus | Description | Strain | |
|---|---|---|---|
| EFC3C | EFC3Py | ||
| OG1RF_12213 | Membrane protein ( | Ile179 (deletion) | — |
| OG1RF_11256 | Site-specific tyrosine recombinase XerD | — | Ala233Val (substitution) |
| OG1RF_11765 | MerR family transcriptional regulator | — | Val134_Asp135insValVal (insertion) |
| OG1RF_11767 | Multidrug ABC transporter ATP-binding protein | — | Thr188Asn (substitution) |
| OG1RF_12211 | DNA-binding response regulator ( | — | Ala98Val (substitution) |
Percentage of total membrane content as determined by fatty acid analysis
| Fatty acid | % of total membrane content | ||
|---|---|---|---|
|
| EFC3C | EFC3Py | |
| C10:0 | 0.00 ± 0.00 | 0.05 ± 0.05 | 0.02 ± 0.04 |
| C12:0 | 0.29 ± 0.24 | 0.19 ± 0.25 | 0.20 ± 0.28 |
| C14:0 | 3.55 ± 0.27 | 3.61 ± 0.46 | 3.46 ± 0.42 |
| C15:1 ω8c | 0.06 ± 0.12 | 0.00 ± 0.00 | 0.07 ± 0.10 |
| C16:0 | 40.07 ± 1.03 | 37.73 ± 1.55* | 36.78 ± 0.66* |
| C17:0 cyclo | ND | 0.10 ± 0.21 | 0.04 ± 0.09 |
| C17:1 ω8c | 1.24 ± 1.55 | 0.86 ± 1.71 | 0.00 ± 0.00 |
| C18:1 ω7c | 33.85 ± 0.88 | 31.93 ± 1.61* | 35.93 ± 1.43* |
| C18:0 | 5.65 ± 0.70 | 5.26 ± 0.43 | 5.45 ± 0.32 |
| C18:1 ω9c | 0.07 ± 0.13 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| C19:1 | 0.44 ± 0.06 | 0.41 ± 0.05 | 0.36 ± 0.06 |
| C19:0 cyclo ω8c | 7.37 ± 0.56 | 12 ± 0.69* | 10.18 ± 0.37* |
| C19:0 10 methyl | 0.82 ± 0.07 | 1.31 ± 0.28 | 0.98 ± 0.20 |
| C20:2 ω6,9c | 0.00 ± 0.00 | 0.05 ± 0.10 | 0.00 ± 0.00 |
| C20:1 ω7c | 0.40 ± 0.08 | 0.51 ± 0.06 | 0.59 ± 0.10 |
| C16:1 ω7c/15 | 3.92 ± 0.30 | 4.07 ± 0.26 | 4.00 ± 0.25 |
| C15:0 | 1.09 ± 0.08 | 1.10 ± 0.08 | 1.11 ± 0.05 |
| C17:1 | 0.83 ± 0.11 | 0.68 ± 0.06 | 0.62 ± 0.05 |
| Cuneluted peak± | 0.31 ± 0.08 | 0.27 ± 0.09 | 0.20 ± 0.13 |
The values are shown as averages ± standard deviations of five different replicates of E. faecalis OG1RF, EFC3C and EFC3Py. Significant differences between the mutants EFC3C and EFC3Py in comparison to the wild type was calculated using two-way ANOVA and Tukey's multiple comparisons test-and corrected p-values indicated with *p ≤ 0.0001. ±Unknown peak eluted between C14:0 and C16:1 ω7c/15 .
Fig. 2Percentage changes in the three dominant fatty acids (>10% each of the total fatty acid content) determined as a percentage of total membrane content; shown as averages ± standard deviations of five biological replicates of E. faecalis OG1RF wild type, EFC3C and EFC3Py. Significant differences between the mutants EFC3C and EFC3Py compared to the wild type was calculated using two-way ANOVA and Tukey's multiple comparisons test and corrected p-values indicated with *p ≤ 0.0001.
Fig. 3The relative uptake of 5 μM COEs in E. faecalis OG1RF wild type (WT), EFC3C and EFC3Py determined by measuring the absorbance at the wavelength of maximum absorbance of a 5 μM solution of COEs. Significant differences between the treatments in the respective strains was calculated by t-test and p-values indicated with *p ≤ 0.01.
Fig. 4QCM-D monitoring of COE interactions with supported lipid bilayers. Resonance frequency (Δf) and energy dissipation (ΔD) signals are presented as functions of time. The baseline signals correspond to fabricated SLBs on silica-coated sensor chips, and 5 μM COE compounds were added starting at t = 5 min under continuous flow conditions. All measurement shifts are relative to equivalent buffer conditions.
Fig. 5Electrochemical impedance spectroscopy (EIS) measurements using a tethered lipid bilayer membrane platform. Increasing concentrations of compound were added at the indicated time point. Control is standard tBLM lipid composition without bacterial cell lipid extract.